33 results about "Poorly differentiated" patented technology

Methods of diagnosing whether an epithelial tissue is an abnormal tissue by determining an expression pattern for PML in the epithelial tissue; determining an expression pattern for nuclear bodies in the epithelial tissue; determining SUMO-1 colocalization and comparing the expression pattern for PML and the expression pattern for nuclear bodies with a control are disclosed. Also disclosed are methods for diagnosing whether a subject has mild dysplasia, moderate dysplasia, Type A severe dysplasia, Type B severe dysplasia, cervical squamous cell carcinoma, or poorly-differentiated cervical squamous cell carcinoma, by determining an expression pattern for PML, an expression pattern for nuclear bodies, and SUMO-1 colocalization and determining whether the sample is consistent with expression patterns expected for mild dysplasia, moderate dysplasia, Type A severe dysplasia, Type B severe dysplasia, cervical squamous cell carcinoma, or poorly-differentiated cervical squamous cell carcinoma.

The invention relates to a breast cancer recurrent risk assessment 21 gene detection primer and application thereof. The breast cancer recurrent risk assessment 21 gene detection primer comprises a nucleotide sequence as shown in an SEQ ID NO.: 1 to 42, and belongs to the technical field of molecular detection. The detection primer provided by the invention utilizes the advantage of fluorescent quantitation, and adopts fluorescent quantitation polymerase chain reaction to carry out amplification detection on 21 genes for breast cancer recurrent risk assessment, so that whether clinical measurements such as adjuvant chemotherapy are needed or not is considered. A kit provides a PCR (Polymerase Chain Reaction) amplification primer sequence of the 21 genes for breast cancer recurrent risk assessment, and the primer is applicable to detecting ER positive patients, HER2 negative patients, axillary node negative patients, moderately and poorly differentiated patients with the tumor size being 0.6 to 1.0cm and adverse prognostic factors, or patients with the tumor size is larger than 1cm, has the advantages of high sensitivity and specificity, stability, promptness, convenience in operation and the like, can well meet the clinical application of breast cancer recurrent risk assessment, and can be beneficial for reducing invalid medication administration, improving medication administration accuracy, and reducing financial burdens of the patients.

Phage display was used to screen peptide libraries that distinguish between well-differentiated (HCT116) and poorly-differentiated colon carcinoma cells (HT29). The screening protocol used selection and subtraction on intact, viable cells, resulting in phage libraries exhibiting high binding selectivity for the poorly-differentiated HT29 cells. A nine amino acid, disulfide-constrained peptide (RPM) was identified that selectively bound and was internalized into colon cancer cells. The peptide may be used to detect colon cancer cells and also may be used to selectively deliver therapeutic agents to the cells.

The invention belongs to the technical field of image analysis, in particular to a microscopic image analysis method of a cervical cancer tissue based on a graph theory. The microscopic image analysismethod of the cervical cancer tissue based on the graph theory includes the following steps: collecting microscopic image data of cervical cancer tissue, segmenting each original image by different algorithms, and fusing the segmentation results to obtain fused images; according to the morphological and textural features of the nuclei, the fusion images were classified into three categories: highly differentiated, moderately differentiated and poorly differentiated; comprehensive assessment of classification results are performed. The present application uses fused segmentation algorithms toenhance accuracy, form a complete classification process, and make classification evaluations. Pathological images of cervical cancer can be divided into three types: well differentiated, moderately differentiated and poorly differentiated according to the spatial structure of the nucleus, which can be used in the daily practice of histologists to speed up the time of diagnosis and improve the accuracy of diagnosis.

The invention discloses a 5,8-disubstituted-1,6-quinazoline-7-amidocarbonylation compound, a preparing method, an application and a drug composite containing the compound thereof. More specifically, the invention discloses a 5,8-disubstituted-1,6-quinazoline-7-amidocarbonylation compound as shown in the formula I, a preparing method and an application thereof. By the growth inhibition test of various tumour cell lines (human breast cancer cells MDA-MB-435, p53-deleted poorly differentiated colorectal adenocarcinoma cells Hct116p53-/-, p53-enriched poorly differentiated colorectal adenocarcinoma cells Hct116p53+/+, human breast cancer cells Mcf-7, NIH189, human breast cancer cells SkBr-3, prostatic cancer cells LnCap, LnHer, human colorectal cancer cells HT29 and human ovarian cancer cellsHEY), the compound has favourable inhibition activity for the above tumour cells and can treat diseases caused by tumour cell malignant proliferation. The invention also discloses a drug composite containing the compound.

The invention relates to Papanicolaou staining fluid and a using method thereof. The Papanicolaou staining fluid consists of fluid A, fluid B and 95 percent ethanol, wherein the fluid A is improved hematoxylin staining fluid; the fluid B is prepared from a phosphotungstic acid, eostm and light green. A method for preparing the improved hematoxylin staining fluid comprises the following steps of dissolving hematoxylin into the 95 percent ethanol, dissolving potassium alum into 100 DEG C boiling water, mixing two mixed solutions, adding an oxidant, stirring for at least 50 minutes, adding a glacial acetic acid, and stirring for at least 50 minutes. A method for preparing the fluid B comprises the following steps of mixing 95 to 97 mass percent of 0.2 to 0.6 percent phosphotungstic acid solution, 1.5 to 2.5 mass percent of eostm solution and 1.5 to 2.5 mass percent of light green solution. When the Papanicolaou staining fluid is used, a smear is fixed in the 95 percent ethanol, and is flushed in a specific environment by adding a corresponding amount of fluid A and a corresponding amount of fluid B. The Papanicolaou staining fluid has the advantages of low cost, bright color, clear contrast, coloring stability, is simple to prepare and convenient to operate, is easily popularized and used in various medical units and the like, and is applied to the display and diagnosis of the estrogen level of a vaginal smear and the poorly-differentiated small-angle cell carcinoma of a cervical smear and a sputum smear.

The invention provides a hairpin polyamide compound (I) modified by chiral (S)-beta-hydroxyl-gamma-amino acid, and an application for the same in preparation of anti-tumour medicines. The compound is of a hairpin structure, and contains (S)-beta-hydroxyl-gamma-amino acid residue (S gamma beta-OH) with a specific identification function for the basic group T of DNA (deoxyribonucleic acid); additionally, the compound further contains common N-methylpyrrole residue (Py), N-methylimidazole residue (Im), gamma-amino acid residue and beta-alanine residue. Experiments indicate that the hairpin polyamide compound provided by the invention has a strong killing effect on tumour cells BEL7402 (liver cancer) and MKN45 (poorly-differentiated gastric cancer), and the compound III is the strongest in expression, and has essential significance on research and development for anti-tumour gene targeted medicines down-regulated by chirally-modified polyamide mediate c-kit gene.

Methods of treating a disease or disorder characterized by cells with increased or aberrant expression of cytokeratin-8 (CK8) are disclosed. The methods typically include administering to a subject in need thereof a pharmaceutical composition including an effective amount of a CK8 inhibitor. Exemplary diseases include thyroid cancers, particularly thyroid cancers characterized by poorly differentiated or undifferentiated cells. In the most preferred embodiments the cancer is an anaplastic thyroid cancer or a poorly differentiated papillary thyroid cancer. Disclosed inhibitors include, functional nucleic acids, inhibitory anti-CK8 antibodies, inhibitory peptides, and small molecules.

The invention discloses a method for constructing a liver cancer patient-derived chick chorioallantoic membrane M-PDX model. The method comprises the following steps: clinical sample transport, cryopreservation, resuscitation and transplantation. A human hepatic transplantable tumor and an angiogenesis model thereof are established on the chick chorioallantoic membrane (CAM) by using human hepatoma cells with poor differentiation and high metastasis to provide a simple and practical way for the study of hepatic transplantable tumor and angiogenesis thereof. Compared with conventional models, the model has the unique advantages of short experimental period, low cultivation cost, and convenience in operation.

The invention discloses an application of borneol in promoting a poorly differentiated nasopharyngeal cell to intake adriamycin through chloride channel mediation. With the human poorly differentiated nasopharyngeal cell (CNE-2Z) as a research object, the conclusions are explored from the angle of the chloride channel as follows: (1) the chloride channel can be an action target point of the borneol in promotion of adriamycin transportation across a CNE-2Z cytomembrane; (2) the borneol can activate a CNE-2Z cell chloride current, and the current has volume sensitivity; (3) the ClC-3 chloride channel plays an important role in promotion of adriamycin transportation across the CNE-2Z cytomembrane by the borneol; and (4) the anti-tumor effect of the adriamycin can be obviously improved by combination of the borneol and the adriamycin. The mechanism of the borneol in promotion of drug uptake through the cytomembrane is expected to be diluted from the angle of the chloride channel by discussing the relationship between the chloride channel and the drugs taken by the cell in different states; and a new theoretical basis is provided for the borneol in clinical application.

Provided are methods and kits for staining cervical cell sample by contacting the cervical cell sample with a Ficus elastics plant extract, staining the cervical cell sample with New Fuchsin, and staining the cervical cell sample with Light Green or Fast Green. Also provided are method of diagnosing a pre-malignant or a malignant cervical tumor in a subject, by staining the cervical cell sample and identifying at least one cervical cell having a red cytoplasm above a pre-determined threshold, wherein presence of the at least one cervical cell having the red cytoplasm above the pre-determined threshold is indicative of a non- or less-differentiated cell as compared to a normal cervical cell, thereby diagnosing the pre-malignant or a malignant cervical tumor in the subject.

The invention discloses an SIX4 gene used as a molecular marker for assessing the malignant degree of oral squamous cell carcinoma. High-throughput sequencing and QPCR studies show that the content ofthe SIX4 gene in high differentiated oral squamous cell carcinoma is lower than that in low differentiated oral squamous cell carcinoma. According to the research results, the invention can also develop a kit for assessing the malignant degree of oral squamous cell carcinoma, which has a remarkable detection effect and can be widely popularized and applied in clinic.

The invention discloses a traditional Chinese medicine preparation for relieving gastric poorly differentiated adenocarcinoma. The traditional Chinese medicine preparation is prepared from astragalus membranaceus, rhizoma paridis chinensis, sun-dried ginseng, stir-fried largehead atractylodes rhizome, stir-fried white peony roots, rhodiola rosea, Chinese angelica, prepared rehmannia roots, rhizoma smilacis glabrae, Indian iphigenia bulb, barbed skullcap herb, rhizoma chuanxiong, rhizoma curcumae, wild buckwheat rhizome, suberect spatholobus stems, ganoderma lucidum, raw semen coicis, yangtao actinidia roots, wild chrysanthemum flowers, asiatic moonseed rhizome, flos sophorae and raw liquorice in a certain weight ratio. The traditional Chinese medicine preparation has the efficacy of clearing heat, removing toxicity, eliminating carbuncle, removing stasis, promoting the production of body fluid to relieve thirst, strengthening spleen and benefiting qi and can inhibit cancer cell spreading and strengthen physique of a patient, thereby controlling and relieving gastric poorly differentiated adenocarcinoma.

The invention discloses a tumor tissue in-vitro pathological staining kit. The tumor tissue in-vitro pathological staining kit is a kit developed aiming at leading Cetuximab to be used in new applications of tumor tissue in-vitro pathological staining, experiments verification finds that after the Cetuximab is subjected to fluorescent labeling and then used for tumor tissue in-vitro pathological staining, normal tissues and tumor tissues can be well distinguished, well-differentiated and poorly-differentiated tumor tissues can be distinguished to certain extent, and the kit can be used for tumor detection, thus realizing new use for approved drugs.

The invention discloses a monoclonal antibody resisting the ovarian cancer and application thereof. A hybridoma cell strain NM003-1 secreting the monoclonal antibody resisting the human ovarian cancer is preserved in China Center for Type Culture Collection on September 26, 2011 with the preservation number of CCTCC NO: C201174. The hybridoma cell strain NM003-1 secretes the monoclonal antibody NJ003-1 resisting the human ovarian cancer. Expression of a specific antigen of the monoclonal antibody NJ003-1 in ovarian cancer tissue is higher than that in ovarian benign disease tissue; the positive expression rate of the antigen in a poorly differentiated patient is higher than that in a well differentiated patient. The monoclonal antibody NJ003-1 can effectively inhibit clone formation of ovarian carcinoma cells SK-OV-3 in soft agar and can remarkably inhibit growth of human ovarian cancer transplantation tumors in a nude mouse. Obviously, the monoclonal antibody is expected to become medicine for treating the ovarian cancer or to be prepared into a diagnostic reagent for detecting the ovarian cancer.